Q4 2019 Eli Lilly and Co Earnings Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q4 2019 Earnings Call. (Operator Instructions) As a reminder, today's call is being recorded.
I'd now like to turn the conference over to your host, Kevin Hern. Please go ahead.
Good morning. Thank you for joining us for Eli Lilly and Company's Q4 2019 Earnings Call.
I'm Kevin Hern, Vice President of Investor Relations. Joining on today's call are Dave Ricks, Lilly's Chairman and CEO; Josh Smiley, Chief Financial Officer; Dr. Dan Skovronsky, Chief Scientific Officer; Anne White, President of Lilly Oncology; Patrik Jonsson, President of Lilly Bio-Medicines; and Mike Mason, President of Lilly Diabetes. We're also joined by Kim Macko and Mike Czapar of the Investor Relations team.
During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to a number of factors, including those listed on Slide 3 and those
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |